Bright Minds Biosciences (DRUG) Operating Leases (2022 - 2025)

Bright Minds Biosciences' Operating Leases history runs 4 years deep, the most recent figure standing at $29973.0 for Q3 2025.

• Quarterly Operating Leases rose 3.31% year-over-year to $29973.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $29973.0 (up 3.31% YoY) and the FY2025 annual result came in at $29973.0, up 3.31% from the prior year.
• Operating Leases was $29973.0 for Q3 2025 at Bright Minds Biosciences, down from $78792.1 in the prior quarter.
• Across five years, Operating Leases topped out at $107276.2 in Q3 2022 and bottomed at $29011.3 in Q3 2024.
• A 4-year average of $59983.0 and a median of $54862.4 in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2023 — Operating Leases sank 48.86% — and 2025, when it advanced 3.31%.
• Bright Minds Biosciences' Operating Leases stood at $107276.2 in 2022, then plunged by 48.86% to $54862.4 in 2023, then jumped by 43.62% to $78792.1 in 2024, then plunged by 61.96% to $29973.0 in 2025.
• Business Quant data shows DRUG's Operating Leases at $29973.0 in Q3 2025, $78792.1 in Q4 2024, and $29011.3 in Q3 2024.